Dr. Nayef Mohammed A. Kazzaz, MD

Dr. Kazzaz practices at Arthritis Medical Clinic in Riverside, California.

Dr. Kazzaz's NPI, 1316234693, was assigned on July 7, 2011. Dr. Kazzaz graduated from King Saud University College of Medicine in 2009. Dr. Kazzaz's Kentucky license number on file is 51325.

Dr. Kazzaz's primary practice is Arthritis Medical Clinic, at 6180 Brockton Ave Suite 204 Suite 204, Riverside, CA 92506-2233. The practice phone is (951) 781-7700.

Dr. Kazzaz's primary practice is Arthritis Medical Clinic in Riverside, California. The medical group on file is Arthritis Medical Clinic. Dmand AI also links Dr. Kazzaz to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kazzaz practices. Vendor and product names are available with a free account.

Rheumatology is Dr. Kazzaz's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Kazzaz is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kazzaz's licenses on file in 5 states: Kentucky, California, Michigan, Ohio and Florida.

Dmand AI lists arteritis, arthritis, joint arthropathy, joint pain, lupus, muscle pain, fibromyalgia, and limb pain, osteoporosis and rheumatoid arthritis among the conditions Dr. Kazzaz treats.

CMS data shows 2,324 Medicare services from Dr. Kazzaz across 12 procedure codes in 2024, for 115 Medicare patients. Medicare paid $52,083 for them. Every service was in an office.

CMS counts 115 Medicare patients who saw Dr. Kazzaz in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have arthritis, and 75% have high blood pressure. 59% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kazzaz's median patient age at 56, with 81% women.

In 2024, Dr. Kazzaz wrote 850 Medicare Part D claims for 189 patients. 64% of them were for generic drugs. CMS names the drug for 699 of them, across 21 drugs with 11 or more claims each, at $1,072,516 in total drug cost. In 2023, CMS named 760 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kazzaz for performance year 2024, reported as part of a group. Dr. Kazzaz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Kazzaz, published from 2013 to 2018. 2015 was the busiest year, with 3. The most frequent topics are Antiphospholipid Syndrome and Glucocorticoids. Dr. Kazzaz has published most often in Lupus Sci Med. Dr. Kazzaz's most frequent co-authors are Jason S. Knight, MD, Paula L. Bockenstedt, MD and Ahmed Abdel-Latif, MD.

CMS Open Payments shows 130 general payments to Dr. Kazzaz from 21 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 91% of the total. Amgen Inc. paid the most, $770.

Dr. Kazzaz graduated from King Saud University College of Medicine in 2009.

Dr. Kazzaz is in network with 17 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.